الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 74 |  |  |
| | | from | 74 | | |
Abstract
A new coronavirus, which was responsible for the viral epidemic in December 2019, originated from Wuhan in the Chinese province of Hubei. It has spread over the globe and emerged as one of the most serious risks to public health. The condition was referred to as coronavirus disease 2019 (COVID-19) and the virus was known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 was considered to be a ”pandemic” by the WHO on March 11, 2020.
Pregnancy-related physiologic and immunologic changes may have systemic consequences that put women at risk for respiratory infection problems that can cause maternal and fetal adverse outcomes. Pregnant women were known to experience negative consequences from SARS-CoV1 and MERS-CoV, which both had high case fatality rates. It is fair to anticipate that pregnant women are likely to contract SARS-CoV-2 due to its rapid dissemination.
Concerns have been raised around the world regarding the clinical manifestations and rate of vertical transmission of COVID-19. Many questions were asked including the following: whether manifestations of the disease differ in pregnant females from those in non-pregnant females; whether complications of the disease and case fatality are higher in pregnant females in comparison to non-pregnant females; and the nature and rate of neonatal adverse outcomes including fetal mortality. Answering these questions are of great importance for planning adequate obstetrical management for those patients.